Bisphosphonates in the treatment of malignant bone disease

James R. Berenson, Allan Lipton

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

Original languageEnglish (US)
Pages (from-to)237-248
Number of pages12
JournalAnnual Review of Medicine
Volume50
DOIs
StatePublished - Mar 17 1999

Fingerprint

Bone Diseases
Diphosphonates
Bone
Osteoclasts
Bone Resorption
Neoplasm Metastasis
Osteitis Deformans
Bone and Bones
Neoplasms
Osteolysis
Reducing Agents
Hypercalcemia
Multiple Myeloma
Double-Blind Method
Tumors
Therapeutics
Breast Neoplasms
Byproducts
Chemical activation

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{66bdd52895a54cb0b15deb659e73c763,
title = "Bisphosphonates in the treatment of malignant bone disease",
abstract = "Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.",
author = "Berenson, {James R.} and Allan Lipton",
year = "1999",
month = "3",
day = "17",
doi = "10.1146/annurev.med.50.1.237",
language = "English (US)",
volume = "50",
pages = "237--248",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

Bisphosphonates in the treatment of malignant bone disease. / Berenson, James R.; Lipton, Allan.

In: Annual Review of Medicine, Vol. 50, 17.03.1999, p. 237-248.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bisphosphonates in the treatment of malignant bone disease

AU - Berenson, James R.

AU - Lipton, Allan

PY - 1999/3/17

Y1 - 1999/3/17

N2 - Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

AB - Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0032976794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032976794&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.50.1.237

DO - 10.1146/annurev.med.50.1.237

M3 - Review article

VL - 50

SP - 237

EP - 248

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -